You are here

Nature DOI:10.1038/s41586-019-1102-x

WRN helicase is a synthetic lethal target in microsatellite unstable cancers.

Publication TypeJournal Article
Year of Publication2019
AuthorsChan, EM, Shibue, T, McFarland, JM, Gaeta, B, Ghandi, M, Dumont, N, Gonzalez, A, McPartlan, JS, Li, T, Zhang, Y, Bin Liu, J, Lazaro, J-B, Gu, P, Piett, CG, Apffel, A, Ali, SO, Deasy, R, Keskula, P, Ng, RWS, Roberts, EA, Reznichenko, E, Leung, L, Alimova, M, Schenone, M, Islam, M, Maruvka, YE, Liu, Y, Roper, J, Raghavan, S, Giannakis, M, Tseng, Y-Y, Nagel, ZD, D'Andrea, A, Root, DE, Boehm, JS, Getz, G, Chang, S, Golub, TR, Tsherniak, A, Vazquez, F, Bass, AJ
JournalNature
Date Published2019 Apr 10
ISSN1476-4687
Abstract

Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics. DNA repair processes represent attractive synthetic lethal targets, because many cancers exhibit an impairment of a DNA repair pathway, which can lead to dependence on specific repair proteins. The success of poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors in cancers with deficiencies in homologous recombination highlights the potential of this approach. Hypothesizing that other DNA repair defects would give rise to synthetic lethal relationships, we queried dependencies in cancers with microsatellite instability (MSI), which results from deficient DNA mismatch repair. Here we analysed data from large-scale silencing screens using CRISPR-Cas9-mediated knockout and RNA interference, and found that the RecQ DNA helicase WRN was selectively essential in MSI models in vitro and in vivo, yet dispensable in models of cancers that are microsatellite stable. Depletion of WRN induced double-stranded DNA breaks and promoted apoptosis and cell cycle arrest selectively in MSI models. MSI cancer models required the helicase activity of WRN, but not its exonuclease activity. These findings show that WRN is a synthetic lethal vulnerability and promising drug target for MSI cancers.

DOI10.1038/s41586-019-1102-x
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30971823?dopt=Abstract

Alternate JournalNature
PubMed ID30971823